Publications by authors named "Yu Na Chae"

Claim this Profile
A
Additive effects of evogliptin in combination with pioglitazone on fasting glucose control through direct and indirect hepatic effects in diabetic mice.
Tae-Hyoung Kim, Jeong-Ha Lee, Yu Na Chae, Il-Hoon Jung, Mi-Kyung Kim

Eur J Pharmacol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloid Sirtuin 6 Deficiency Causes Insulin Resistance in High-Fat Diet-Fed Mice by Eliciting Macrophage Polarization Toward an M1 Phenotype.
Youngyi Lee, Sun-O Ka, Hye-Na Cha, Yu-Na Chae, Mi-Kyung Kim

Diabetes· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models.
Mi-Kyung Kim, Yu Na Chae, Gook-Jun Ahn, Chang Yell Shin, Song-Hyen Choi

Arch Pharm Res· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice.
Yu-Na Chae, Tae-Hyoung Kim, Mi-Kyung Kim, Chang-Yell Shin, Il-Hoon Jung

PLoS One· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic role in an early glucose-lowering effect by a novel dipeptidyl peptidase 4 inhibitor, evogliptin, in a rodent model of type 2 diabetes.
Tae-Hyoung Kim, Mi-Kyung Kim, Ye-Hwang Cheong, Yu-Na Chae, Youngyi Lee

Eur J Pharmacol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes.
Mi-Kyung Kim, Yu Na Chae, Ha Dong Kim, Eun Kyoung Yang, Eun Jung Cho

Life Sci· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Heung Jae Kim, Woo Young Kwak, Jong Pil Min, Jae Young Lee, Tae Hyun Yoon, Yu Na Chae

Bioorg Med Chem Lett· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
Mi-Kyung Kim, Yu Na Chae, Song-hyen Choi, Ho Sang Moon, Moon-Ho Son

Eur J Pharmacol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Mi-Kyung Kim, Yu Na Chae, Hae Sun Kim, Song-hyen Choi, Moon Ho Son

Arch Pharm Res· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
Mi-Kyung Kim, Yu Na Chae, Moon Ho Son, Soon Hoe Kim, Jin Kwan Kim

Eur J Pharmacol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.
Young-Ger Suh, Nam-Jung Kim, Bon-Woong Koo, Kwang-Ok Lee, Sung-Hyun Moon, Yu Na Chae

J Med Chem· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis